The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Advanced gastric cancer: Current treatment landscape and future perspectives
Open accessAbstract
Gastric cancer currently ranks fourth in cancer-related mortality worldwide. In the western world, it is most often diagnosed at an advanced stage, after becoming metastatic at distant sites. Patients with advanced disease (locally advanced or metastatic) have a somber prognosis, with a median overall survival of 10-12 mo, and palliative chemotherapy is the mainstay of treatment. In recent years, novel approaches using inhibition of human epidermal growth factor receptor 2 (HER2) have demonstrated significant improvements in progression-free and overall survival, compared with chemotherapy alone, in first-line treatment of patients with overexpression of HER2. In addition, both second-line chemotherapy and treatment with the vascular endothelial growth factor receptor-inhibitor ramucirumab demonstrated significant benefits in terms of overall survival, compared with best supportive care, in randomized studies. Moreover, ramucirumab in combination with chemotherapy demonstrated further significant benefits in terms of progression-free and overall survival, compared with chemotherapy alone, in second-line treatment for patients with metastatic gastric cancer. A recently published molecular classification of gastric cancer is expected to improve patient stratification and selection for clinical trials and provide a roadmap for future drug development. Nevertheless, despite these developments the prognosis of patients with advanced gastric cancer remains poor. In this review we discuss current standards of care and outline major topics of drug development in gastric cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0245 · Cited by 1,171
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Lordick, F., Kang, Y.-K., Chung, H.-C., Salman, P., Oh, S. C., Bodoky, G., Kurteva, G., Volovat, C., Moiseyenko, V. M., Gorbunova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70102-5 · Cited by 833
Al-Batran, S.-E., Hartmann, J. T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., Rethwisch, V., Seipelt, G., Homann, N., Wilhelm, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9378 · Cited by 782
Kang, Y.-K., Kang, W.-K., Shin, D.-B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn717 · Cited by 764
Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A. F. C., Wotherspoon, A., Saffery, C., Middleton, G., Wadsley, J., Ferry, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70096-2 · Cited by 725
Kang, J. H., Lee, S. I., Lim, D. H., Park, K.-W., Oh, S. Y., Kwon, H.-C., Hwang, I. G., Lee, S.-C., Nam, E., Shin, D. B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4585 · Cited by 660
Deng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
Maeda, K., Chung, Y.-S., Ogawa, Y., Kang, S.-M., Ogawa, M., Sawada, T., & Sowa, M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a · Cited by 627
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624
Hecht, J. R., Bang, Y.-J., Qin, S. K., Chung, H. C., Xu, J. M., Park, J. O., Jeziorski, K., Shparyk, Y., Hoff, P. M., Sobrero, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6598 · Cited by 624
Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G., & Reichardt, P. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.002 · Cited by 612
Ford, H. E. R., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., Mansoor, W., Fyfe, D., Madhusudan, S., Middleton, G. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70549-7 · Cited by 595
Boku, N., Yamamoto, S., Fukuda, H., Shirao, K., Doi, T., Sawaki, A., Koizumi, W., Saito, H., Yamaguchi, K., Takiuchi, H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70259-1 · Cited by 586
Yamada, Y., Higuchi, K., Nishikawa, K., Gotoh, M., Fuse, N., Sugimoto, N., Nishina, T., Amagai, K., Chìn, K., Niwa, Y., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu472 · Cited by 567
Ajani, J. A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., Vynnychenko, I., Garin, A., Lang, I., & Falcon, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4706 · Cited by 550
Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5805 · Cited by 541
Ohtsu, A., Ajani, J. A., Bai, Y.-X., Bang, Y.-J., Chung, H.-C., Pan, H.-M., Sahmoud, T., Shen, L., Yeh, K.-H., Chin, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3552 · Cited by 483
Chemotherapy for advanced gastric cancer
Wagner, A. D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., & Fleig, W. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub3 · Cited by 472
Gastric cancer: global pattern of the disease and an overview of environmental risk factors
Forman, D., & Burley, V. J. (2006) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2006.04.008 · Cited by 457
Dank, M., Zaluski, J., Barone, C., Valvere, V., Yalcin, S., Peschel, C., Wenczl, M., Goker, E., Cisar, L., Wang, K., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn166 · Cited by 343
Iveson, T., Donehower, R. C., Davidenko, I., Tjulandin, S., Deptala, A., Harrison, M., Nirni, S., Lakshmaiah, K., Thomas, A., Jiang, Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70023-3 · Cited by 265
Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., André, T., Gornet, J.-M., Aparicio, T., Nguyen, S., Azzedine, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1011 · Cited by 263
Ajani, J. A., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4968 · Cited by 250
Soman, N. R., Correa, P., Ruiz, B. A., & Wogan, G. N. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4892 · Cited by 190
Yamashita-Kashima, Y., Iijima, S., Yorozu, K., Furugaki, K., Kurasawa, M., Ohta, M., & Fujimoto-Ouchi, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2927 · Cited by 176
The JACCRO and KCSG Study Group, Koizumi, W., Kim, Y. H., Fujii, M., Kim, H. K., Imamura, H., Lee, K. H., Hara, T., Chung, H. C., Satoh, T., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1563-5 · Cited by 175
Al-Batran, S.-E., Pauligk, C., Homann, N., Hartmann, J. T., Moehler, M., Probst, S., Rethwisch, V., Stoehlmacher-Williams, J., Prasnikar, N., Hollerbach, S., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.025 · Cited by 165
Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer
Song, Z.-J. (2002) · World Journal of Gastroenterology · doi:10.3748/wjg.v8.i4.591 · Cited by 129
Hecht, J. R., Bang, Y., Qin, S., Chung, H.-C., Xu, J., Park, J. O., Jeziorski, K., Shparyk, Y. V., Hoff, P. M., Sobrero, A. F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.lba4001 · Cited by 127
Ryu, M., Yoo, C., Kim, J. G., Ryoo, B., Park, Y. S., Park, S. R., Han, H., Chung, I. J., Song, E., Lee, K. H., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.015 · Cited by 126
Satoh, T., Lee, K., Rha, S., Sasaki, Y., Park, S., Komatsu, Y., Yasui, H., Kim, T.-Y., Yamaguchi, K., Fuse, N., et al. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0420-9 · Cited by 123
Muro, K., Bang, Y., Shankaran, V., Geva, R., Catenacci, D. V. T., Gupta, S., Eder, J. P., Berger, R., Gonzalez, E. J., Ray, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.3 · Cited by 118
Shah, M. A., Bang, Y., Lordick, F., Tabernero, J. M., Chen, M., Hack, S. P., Phan, S., Shames, D. S., & Cunningham, D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4012 · Cited by 104
Kang, Y.-K., Rha, S. Y., Tassone, P., Barriuso, J., Yu, R., Szado, T., Garg, A., & Bang, Y.-J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.356 · Cited by 96
Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer
McDermott, J. D., & Jimeno, A. (2015) · Drugs of today · doi:10.1358/dot.2015.51.1.2250387 · Cited by 84
Quality of Life in the Trastuzumab for Gastric Cancer Trial
Satoh, T., Bang, Y., Gotovkin, E., Hamamoto, Y., Kang, Y., Moiseyenko, V. M., Ohtsu, A., Cutsem, E. V., Al-Sakaff, N. J. A., Urspruch, A., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0058 · Cited by 64
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Eberhardt, W., de Marinis, F., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.010 · Cited by 59
Moehler, M. H., Kanzler, S., Geißler, M., Raedle, J., Ebert, M., Daum, S., Flieger, D., Seufferlein, T. T. W., Galle, P. R., & Hoehler, T. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp269 · Cited by 54
Bang, Y., Chung, H.-C., Shankaran, V., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4001 · Cited by 45
Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
Zhu, M., Tang, R. F., Doshi, S., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.649 · Cited by 42
Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer
Paul, B., Trovato, J. A., & Thompson, J. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070646 · Cited by 36
Chua, C. W. L., Tan, I. B., Yamada, Y., Rha, S. Y., Yong, W. P., Ong, W. S., Tham, C. K., Ng, M. C. H., Tai, D. W.-M., Iwasa, S., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2811-y · Cited by 32
Kim, C., Mulder, K. E., & Spratlin, J. L. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0006 · Cited by 26
Hegewisch‐Becker, S., Moorahrend, E., Kröning, H., Petersen, V., Hannig, C. V., Pott, D., Tirier, C., Lerchenmuller, C. A., Schlag, R., Schneider-Kappus, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4065 · Cited by 11
Research works printed but not linked: 10
- Combined modality approaches to cancer therapy. Council on Scientific Affairs. JAMA 1984;251:2398-2407. · doi:10.1001/jama.251.18.2398
- Polkowski W, van Sandick JW, Offerhaus GJ, ten Kate FJ, Mulder J, Obertop H, van Lanschot JJ. Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999;6:290-297. · doi:10.1007/s10434-999-0290-2
- 10.1038/bjc.2012.588 · doi:10.1038/bjc.2012.588
- 10.1093/annonc/mdu496 · doi:10.1093/annonc/mdu496
- 10.1093/annonc/mdt351 · doi:10.1093/annonc/mdt351
- 10.1016/j.ejca.2014.01.020 · doi:10.1016/j.ejca.2014.01.020
- Qin S. Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. 2014 ASCO Annual Meeting, 2014. . · doi:10.1200/jco.2014.32.15_suppl.4003
- Kijima Y, Hokita S, Yoshinaka H, Itoh T, Koriyama C, Eizuru Y, Akiba S, Aikou T. Amplification and overexpression of c-met gene in Epstein-Barr virus-associated gastric carcinomas. Oncology 2002;62:60-65. · doi:10.1159/000048248
- Cunningham D, Davidenko I, Ilson DH, Murad AM, Tebbutt NC, Jiang Y, Loh E, Dubey S. RILOMET-1: An international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. 2013 ASCO Annual Meeting, 2015. . · doi:10.1093/annonc/mdu334.126
- Muro KBY, Shankaran V, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Gonzalez EJ, Pulini J, Ray AB. A phase 1B study of pembrolizumab in patients with advanced gastric cancer. (Abstract LBA15). ESMO Annual Meeting 2014;. · doi:10.1093/annonc/mdu438.15
Cited by
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Wang, Q., Chen, C., Ding, Q., Zhao, Y., Wang, Z., Chen, J., Jiang, Z., Zhang, Y., Xu, G., Zhang, J., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319639 · Cited by 862
Bang, Y.-J., Ruiz, E. Y., Van Cutsem, E., Lee, K.-W., Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M.-H., Chung, H.-C., Evesque, L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy264 · Cited by 501
Recent Advances in the Surgical Treatment of Advanced Gastric Cancer: A Review
Tan, Z. (2019) · Medical Science Monitor · doi:10.12659/msm.916475 · Cited by 427
HER2 testing in gastric cancer: An update
Abrahao-Machado, L. F., & Scapulatempo-Neto, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i19.4619 · Cited by 310
Metadata
- Authors
- Digklia, A.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2016
- Volume
- 22
- Issue
- 8
- Pages
- 2403
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2292909024
- Cited by
- 560
- References
- 56
- FWCI
- 19.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.